Media coverage about Scpharmaceuticals (NASDAQ:SCPH) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Scpharmaceuticals earned a news impact score of 0.17 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 48.7485057029589 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
SCPH has been the subject of several recent research reports. Zacks Investment Research upgraded shares of Scpharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, March 28th. Jefferies Group reissued a “buy” rating and issued a $26.00 price target on shares of Scpharmaceuticals in a report on Wednesday, March 21st.
Shares of SCPH stock opened at $10.94 on Monday. Scpharmaceuticals has a 12-month low of $10.52 and a 12-month high of $18.17. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.12 and a current ratio of 24.12.
Scpharmaceuticals (NASDAQ:SCPH) last announced its quarterly earnings results on Tuesday, March 20th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.27). sell-side analysts anticipate that Scpharmaceuticals will post -2.78 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://ledgergazette.com/2018/04/16/scpharmaceuticals-scph-receives-daily-coverage-optimism-rating-of-0-17.html.
Scpharmaceuticals Company Profile
scPharmaceuticals Inc, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products. The company's under development products are for heart failure and infectious diseases that include Furoscix for the treatment of worsening or decompensated heart failure outside of the inpatient setting.
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.